Shattuck Labs announces positive Phase 1 results for SL-325 DR3 blocking antibody
Shattuck Labs reported Phase 1 data for SL-325 showing a potentially best-in-mechanism immunogenicity profile with only 3.7% antidrug antibodies and complete TL1A blockade lasting over 3 months. The company plans to initiate Phase 2b trials in Crohn's disease in Q3 2026, advancing its pipeline of DR3-targeting therapeutics.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day